In addition to ALK, RET, NTRK1, and ROS1, fusions involving FGFR1/2/3 and NRG1 genes have been reported in NSCLC among other cancers and represent emerging therapeutic targets. Here, NRG1 is linked to non-small cell lung carcinoma.